E-LIB Suche - Ergebnisse für: Falchook, Gerald Steven

1

Outcomes of patients with advanced cancer and KRAS mutation..:

Said, Rabih ; Ye, Yang ; Falchook, Gerald Steven...
Oncotarget. 5 (2014) 19 - p. 8937-8946 , 2014

Link: https://doi.org/10.18632..

2

Outcomes of patients with advanced cancer and KRAS mutation..:

Said, Rabih ; Ye, Yang ; Falchook, Gerald Steven...
qt9m15z9c0. , 2014

Link: https://escholarship.org..

3

Phase I Study of the BRAF Inhibitor Vemurafenib in Combinat..:

Subbiah, Vivek ; Sen, Shiraj ; Hess, Kenneth R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446411/. , 2018

Link: http://www.ncbi.nlm.nih...

4

BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-..:

Falchook, Gerald S ; Millward, Michael ; Hong, David...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291160/. , 2015

Link: http://www.ncbi.nlm.nih...

5

Tumor genetic analyses of patients with metastatic melanoma..:

Nathanson, Katherine L ; Martin, Anne-Marie ; Wubbenhorst, Bradley...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924894. , 2013

Link: http://www.ncbi.nlm.nih...

6

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of ..:

Tolcher, Anthony W ; Messersmith, Wells A ; Mikulski, Stanislaw M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950496/. , 2012

Link: http://www.ncbi.nlm.nih...

7

A phase 2 study of AZD4635 in combination with durvalumab o..:

Falchook, Gerald S. ; Reeves, James ; Gandhi, Sunil...
Cancer Immunology, Immunotherapy. 73 (2024) 4 - p. , 2024

Link: https://doi.org/10.1007/..

8

B7-H3 Inhibitors in Oncology Clinical Trials: A Review:

Feustel, Kavanya ; Martin, Jared ; Falchook, Gerald S.
Journal of Immunotherapy and Precision Oncology. 7 (2024) 1 - p. 53-66 , 2024

Link: https://doi.org/10.36401..

9

Sotorasib with panitumumab in chemotherapy-refractory KRASG..:

Kuboki, Yasutoshi ; Fakih, Marwan ; Strickler, John...
Nature Medicine. 30 (2024) 1 - p. 265-270 , 2024

Link: https://doi.org/10.1038/..

10

Long-Term Benefit of Sotorasib in Patients With KRAS G12C–M..:

Dy, Grace K ; Govindan, Ramaswamy ; Velcheti, Vamsidhar...
Future Oncology. 20 (2023) 3 - p. 113-120 , 2023

Link: https://doi.org/10.2217/..

11

A phase 1/2a safety, pharmacokinetics, and efficacy study o..:

Janku, Filip ; Javle, Milind M. ; Sen, Shiraj...
Cancer. 129 (2023) 10 - p. 1537-1546 , 2023

Link: https://doi.org/10.1002/..

12

A phase Ib study of adavosertib, a selective Wee1 inhibitor..:

Falchook, Gerald S ; Sachdev, Jasgit ; Imedio, Esteban Rodrigo...
Investigational New Drugs. 41 (2023) 3 - p. 493-502 , 2023

Link: https://doi.org/10.1007/..

13

A dose escalation/expansion study evaluating dose, safety, ..:

Dasari, Arvind ; Hamilton, Erika P. ; Falchook, Gerald S....
Investigational New Drugs. 41 (2023) 3 - p. 421-430 , 2023

Link: https://doi.org/10.1007/..

14

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist ..:

Yap, Timothy A. ; Gainor, Justin F. ; Callahan, Margaret K....
Clinical Cancer Research. 28 (2022) 17 - p. 3695-3708 , 2022

Link: https://doi.org/10.1158/..

15

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of..:

Saleh, Mansoor N. ; Patel, Manish R. ; Bauer, Todd M....
Clinical Cancer Research. 28 (2022) 2 - p. 429-429 , 2022

Link: https://doi.org/10.1158/..